文献速递中医妇科中药与中成药合理使用

二陈汤通过调节类固醇生物合成通路改善多囊卵巢综合征大鼠模型

Erchen Decoction ameliorates the rat model of polycystic ovary syndrome by regulating the steroid biosynthesis pathway.
PubMed 文献 · Phytomedicine · 2025-05-20

本研究结合生物信息学预测与letrozole联合高脂饮食诱导的PCOS大鼠模型,探讨二陈汤治疗PCOS的关键成分、机制与靶点。结果显示高剂量二陈汤可降低体重、改善血清激素水平,并调节类固醇激素合成通路中CYP17A1、HSD11B1、AKR1D1和HSD11B2的表达,体外实验验证了关键成分与靶点的结合及细胞水平效应。

要点

  • 高剂量二陈汤可降低PCOS大鼠体重并改善血清T、LH、AMH、FSH水平。
  • 二陈汤通过调节CYP17A1、HSD11B1、AKR1D1、HSD11B2影响类固醇合成。
  • 甘草酸、甘草苷、秦皮乙素、染料木素与CYP17A1等靶点有结合活性。

核心结论

  • 二陈汤通过调节类固醇激素生物合成通路中CYP17A1、HSD11B1、AKR1D1和HSD11B2的表达改善卵巢功能与激素水平。

研究设计与样本

  • 采用生物信息学预测二陈汤成分治疗PCOS的靶点。
  • Sprague-Dawley大鼠设对照(Con)组与PCOS模型组,模型经来曲唑灌胃(1 mg/kg)联合高脂饮食诱导。
  • PCOS组再分组进行28天干预,记录体重、HE染色评估卵巢形态、ELISA检测血清激素。
  • 采用蛋白质组学分析机制与靶点,并用免疫荧光、western blotting和RT-qPCR验证。
  • 在双氢睾酮(DHT)处理的人颗粒细胞KGN中验证关键成分的药理作用。

主要发现

  • Con组和高剂量二陈汤(H-Ecd)组大鼠体重较PCOS组下降。
  • H-Ecd组和二甲双胍组睾酮(T)、促黄体生成素、抗苗勒管激素(AMH)和促卵泡激素水平显著升高(p < 0.05),低剂量二陈汤(l-Ecd)组无显著变化。
  • 主成分分析显示Con、H-Ecd和PCOS组间存在明显差异。
  • 微量热泳动(MST)验证甘草苷、甘草酸、秦皮乙素和染料木素与CYP17A1的结合亲和力分别为5.4、12.55、32.8和17.6 μM。

关键数值与推荐

  • 与PCOS组相比,Con、Met和H-Ecd组CYP17A1和HSD11B1蛋白表达显著降低(p < 0.01),AKR1D1和HSD11B2表达显著升高,l-Ecd组无显著差异。
  • CCK-8实验显示阿比特龙(100 μM)、DHT(100 nM)、甘草酸(50 μM)、甘草苷(600 μM)、染料木素(300 μM)和秦皮乙素(100 μM)显著降低T和AMH水平(p < 0.05)。
  • 与DHT组相比,Con、阿比特龙(Abi)和中药(Tcm)组E2水平显著恢复(p < 0.05)。
  • Western blot显示与DHT组相比,Con、Abi和Tcm组CYP17A1和HSD11B1蛋白表达显著降低(p < 0.01),AKR1D1和HSD11B2表达显著升高(p < 0.01)。

临床怎么用

  • 二陈汤可能通过调节类固醇合成通路关键酶改善PCOS激素紊乱与卵泡发育,高剂量效应更明显。
  • 甘草酸、甘草苷、秦皮乙素和染料木素可作为二陈汤治疗PCOS的潜在活性成分参考。
  • 临床可关注二陈汤对PCOS患者体重及T、LH、AMH、FSH等激素指标的影响,但需结合辨证。

局限性

  • 研究仅基于letrozole联合高脂饮食诱导的大鼠模型与KGN细胞,尚需临床研究验证。
  • 低剂量二陈汤未显示显著效应,剂量与疗程的优化需进一步研究。
  • 原文未报告样本量、随机化与盲法等偏倚控制细节。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Polycystic ovary syndrome (PCOS) is a common endocrine and metabolic disorder associated with chronic inflammation and metabolic issues, including insulin resistance, weight gain, and lipid imbalance. It may cause infertility, menstrual irregularities, and increase the likelihood of developing type 2 diabetes, immune system disturbances, and cardiovascular conditions. OBJECTIVE: To identify the key components, underlying mechanisms, and therapeutic targets of Erchen decoction (ECD) for treating PCOS. METHODS: Abbreviations: Abi group, abiraterone group; AKR, aldo-keto reductase; AMH, anti-Müllerian hormone; BC, betweenness; BP, biological process; BSA, bovine serum albumin; CC, cellular component; CCK-8, cell counting kit-8; Con group, control group; DC, degree centrality; DDA, data-dependent acquisition; DHEA, dehydroepiandrosterone; DHEAS, DHEA sulfate; DHT, dihydrotestosterone; ECD, Erchen decoction; Ecd group, Erchen decoction group; ELISA, enzyme-linked immunosorbent assay; E2, estradiol; FSH, follicle-stimulating hormone; GO, gene ontology; HE, hematoxylin and eosin; H-Ecd group, high-dose Erchen decoction group; HFD, high-fat diet; HSD, hydroxysteroid dehydrogenases; KEGG, Kyoto encyclopedia of genes and genomes; KGN, human granulosa-like tumor cells; LAC, local average connectivity; l-Ecd group, low-dose Erchen decoction group; LH, luteinizing hormone; Met group, metformin (Glucophage) group; MF, molecular function; MIS, Müllerian inhibiting substance; MST, microscale thermophoresis; PCOS model group, PCOS group; PCA, principal component analysis; PCOS, polycystic ovary syndrome; PPI, protein-protein interaction; T, testosterone; TCM, traditional Chinese medicine; Tcm group, traditional Chinese medicine group; UHPLC, ultra-high-performance liquid chromatography Bioinformatics was used to predict the targets of ECD components for treating PCOS. Sprague-Dawley rats were assigned to control (Con) and PCOS model groups. The latter was induced via letrozole (Femara) gavage (1 mg/kg) combined with a high-fat diet. The PCOS group was then subdivided for 28 days of intervention. Body weight was recorded, ovarian morphology was assessed through hematoxylin and eosin staining, and serum hormones were quantified using enzyme-linked immunosorbent assay. Proteomic analyses were performed to examine the underlying mechanisms and potential targets, which were validated using immunofluorescence, western blotting, and RT-qPCR. The pharmacological effects of the key ECD components were confirmed in dihydrotestosterone (DHT)-treated human granulosa KGN cells. RESULTS: The body weight of the rats in the Con and high-dose ECD (H-Ecd) groups decreased compared with that in the PCOS group. The H-Ecd and metformin (Glucophage) groups had significantly elevated levels of testosterone (T), luteinizing hormone, anti-Müllerian hormone (AMH), and follicle-stimulating hormone (p < 0.05), whereas the low-dose Ecd (l-Ecd) group showed no significant change. Thirteen blood-entering components and 168 potential therapeutic targets for PCOS were identified. Kyoto encyclopedia of genes and genomes and gene ontology analyses indicated the involvement of the steroid biosynthesis pathway. Principal component analysis revealed notable differences among the Con, H-Ecd, and PCOS groups. Microscale thermophoresis (MST) validated the binding affinities of liquiritin, glycyrrhizic acid, esculetin, and genistein to cytochrome P450 family 17 subfamily A member 1 (CYP17A1) as 5.4, 12.55, 32.8, and 17.6 μM, respectively. Immunofluorescence, western blotting, and RT-qPCR analyses revealed significantly decreased protein expression of CYP17A1 and 11β-hydroxysteroid dehydrogenase type 1 (HSD11B1) (p < 0.01) and significantly increased the expression of aldo-keto reductase family 1 member D1 (AKR1D1) and HSD11B2 in the Con, Met, and H-Ecd groups relative to that in the PCOS group, whereas the l-Ecd group showed no significant difference. The cell counting kit-8 assay demonstrated that abiraterone (100 μM), DHT (100 nM), glycyrrhizic acid (50 μM), liquiritin (600 μM), genistein (300 μM), and esculetin (100 μM) significantly decreased T and AMH levels (p < 0.05). E2 levels recovered significantly (p < 0.05) in the Con, abiraterone (Abi), and traditional Chinese medicine (Tcm) groups compared to that in the DHT group. Western blot analysis indicated a significant reduction in CYP17A1 and HSD11B1 protein expression (p < 0.01) and a significant increase in AKR1D1 and HSD11B2 expression (p < 0.01) in the Con, Abi, and Tcm groups compared to that in the DHT group. CONCLUSION: We sought to identify the active constituents of ECD for treating PCOS and found that ECD enhances ovarian function by modulating the expression of CYP17A1, HSD11B1, AKR1D1, and HSD11B2 in the steroid hormone biosynthesis pathway resulting in improved hormone levels and follicular development. These results highlight the potential mechanism underlying ECD-mediated effects for PCOS therapy. Molecular docking validated the interaction of liquiritin, glycyrrhizic acid, esculetin, and genistein with CYP17A1, HSD11B1, AKR1D1, and HSD11B2. These interactions were further confirmed in vitro using MST and validated at the cellular level. Our results offer a scientific foundation for the therapeutic application of ECD in PCOS treatment.

来源:Phytomedicine,查看原文。版权归原作者所有。

引用

  1. Zhang J, Huang H, Xiao M, et al. Erchen Decoction ameliorates the rat model of polycystic ovary syndrome by regulating the steroid biosynthesis pathway. Phytomedicine. 2025. PMID: 40446578. doi:10.1016/j.phymed.2025.156852

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。